Key result
FoxO6 deficiency attenuated contractile dysfunction and cardiac remodeling in Ang-II-treated mice, whereas FoxO6 overexpression aggravated cardiomyopathy via the Kif15/TGF-β1 axis.
Why the study?
Pathological cardiac hypertrophy exhibits abnormal gene expression and progresses to heart failure, but the role of transcription factor FoxO6 in cardiac hypertrophy remains to be explored.
Does FoxO6 deficiency prevent Ang-II-induced cardiac remodeling and dysfunction in mice?
Does FoxO6 deficiency prevent Ang-II-induced cardiac remodeling and dysfunction in mice?
FoxO6 promotes pathological cardiac remodeling and dysfunction under aggravated afterload by activating the Kif15/TGF-β1 axis, identifying a potential novel therapeutic target for heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for FoxO6 inhibition in pressure-overload models; leaves open translation to human heart failure therapy.
Pathological cardiac hypertrophy exhibits complex and abnormal gene expression patterns and progresses to heart failure. Forkhead box protein O6 (FoxO6) is a key transcription factor involved in many biological processes. This study aimed to explore the role of FoxO6 in cardiac hypertrophy. Three groups of mice were established: wild-type, FoxO6 knockout, and FoxO6-overexpressing. The mice received daily administration of angiotensin-II (Ang-II) or saline for 4 weeks, after which they were examined for cardiac hypertrophy, fibrosis, and function. Elevated cardiac expression of FoxO6 was observed in Ang-II-treated mice. FoxO6 deficiency attenuated contractile dysfunction and cardiac remodeling, including cardiomyocyte hypertrophy and fibroblast proliferation and differentiation. Conversely, FoxO6 overexpression aggravated the cardiomyopathy and heart dysfunction. Further studies identified kinesin family member 15 (Kif15) as downstream molecule of FoxO6. Kif15 inhibition attenuated the aggravating effect of FoxO6 overexpression. In vitro, FoxO6 overexpression increased Kif15 expression in cardiomyocytes and elevated the concentration of transforming growth factor-β1 (TGF-β1) in the medium where fibroblasts were grown, exhibiting increased proliferation and differentiation, while FoxO6 knockdown attenuated this effect. Cardiac-derived FoxO6 promoted pathological cardiac remodeling induced by aggravated afterload largely by activating the Kif15/TGF-β1 axis. This result further complements the mechanisms of communication among different cells in the heart, providing novel therapeutic targets for heart failure.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied Cardiac hypertrophy. FoxO6 genetic manipulation (knockout or overexpression) vs. Wild-type mice was evaluated on Cardiac hypertrophy, fibrosis, and function. FoxO6 deficiency attenuated contractile dysfunction and cardiac remodeling in Ang-II-treated mice, whereas FoxO6 overexpression aggravated cardiomyopathy via the Kif15/TGF-β1 axis.
Synapse has enriched 10 related papers. Consider them for comparative context: